These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 11978507)

  • 1. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs.
    Mouton JW; Dudley MN; Cars O; Derendorf H; Drusano GL
    Int J Antimicrob Agents; 2002 Apr; 19(4):355-8. PubMed ID: 11978507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update.
    Mouton JW; Dudley MN; Cars O; Derendorf H; Drusano GL
    J Antimicrob Chemother; 2005 May; 55(5):601-7. PubMed ID: 15772142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial pharmacokinetic and pharmacodynamic issues in the critically ill with severe sepsis and septic shock.
    Varghese JM; Roberts JA; Lipman J
    Crit Care Clin; 2011 Jan; 27(1):19-34. PubMed ID: 21144984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics/Pharmacodynamics models of veterinary antimicrobial agents.
    Luo W; Chen D; Wu M; Li Z; Tao Y; Liu Q; Pan Y; Qu W; Yuan Z; Xie S
    J Vet Sci; 2019 Sep; 20(5):e40. PubMed ID: 31565887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of antimicrobial drugs.
    Czock D; Markert C; Hartman B; Keller F
    Expert Opin Drug Metab Toxicol; 2009 May; 5(5):475-87. PubMed ID: 19416084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selecting antibacterials for outpatient parenteral antimicrobial therapy : pharmacokinetic-pharmacodynamic considerations.
    Slavik RS; Jewesson PJ
    Clin Pharmacokinet; 2003; 42(9):793-817. PubMed ID: 12882587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PK-PD Compass: bringing infectious diseases pharmacometrics to the patient's bedside.
    Bulik CC; Bader JC; Zhang L; Van Wart SA; Rubino CM; Bhavnani SM; Sweeney KL; Ambrose PG
    J Pharmacokinet Pharmacodyn; 2017 Apr; 44(2):161-177. PubMed ID: 28353185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can PK/PD be used in everyday clinical practice.
    Scaglione F
    Int J Antimicrob Agents; 2002 Apr; 19(4):349-53. PubMed ID: 11978506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic/pharmacodynamic relationships of antimicrobial drugs used in veterinary medicine.
    McKellar QA; Sanchez Bruni SF; Jones DG
    J Vet Pharmacol Ther; 2004 Dec; 27(6):503-14. PubMed ID: 15601444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic and pharmacodynamic issues for antimicrobial therapy in patients with cancer.
    Theuretzbacher U
    Clin Infect Dis; 2012 Jun; 54(12):1785-92. PubMed ID: 22437238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic and pharmacodynamic evaluation of tigecycline.
    Giamarellou H; Poulakou G
    Expert Opin Drug Metab Toxicol; 2011 Nov; 7(11):1459-70. PubMed ID: 21958044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Animal model pharmacokinetics and pharmacodynamics: a critical review.
    Andes D; Craig WA
    Int J Antimicrob Agents; 2002 Apr; 19(4):261-8. PubMed ID: 11978497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gap analysis of pharmacokinetics and pharmacodynamics in burn patients: a review.
    Steele AN; Grimsrud KN; Sen S; Palmieri TL; Greenhalgh DG; Tran NK
    J Burn Care Res; 2015; 36(3):e194-211. PubMed ID: 25942648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microdialysis for pharmacokinetic-pharmacodynamic studies.
    Yu W; Cheng Q; Feng J; Li F
    Pharmazie; 2007 Dec; 62(12):883-91. PubMed ID: 18214337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunology.
    Barker CI; Germovsek E; Hoare RL; Lestner JM; Lewis J; Standing JF
    Adv Drug Deliv Rev; 2014 Jun; 73(100):127-39. PubMed ID: 24440429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The contribution of pharmacokinetic-pharmacodynamic modelling with Monte Carlo simulation to the development of susceptibility breakpoints for Neisseria meningitidis.
    Burgess DS; Frei CR; Lewis Ii JS; Fiebelkorn KR; Jorgensen JH
    Clin Microbiol Infect; 2007 Jan; 13(1):33-9. PubMed ID: 17184285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic/pharmacodynamic relationship of danofloxacin against Mannheimia haemolytica in a tissue-cage model in calves.
    Greko C; Finn M; Franklin A; Bengtsson B
    J Antimicrob Chemother; 2003 Aug; 52(2):253-7. PubMed ID: 12865390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Class-dependent relevance of tissue distribution in the interpretation of anti-infective pharmacokinetic/pharmacodynamic indices.
    Barbour A; Scaglione F; Derendorf H
    Int J Antimicrob Agents; 2010 May; 35(5):431-8. PubMed ID: 20219329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic-pharmacodynamic analysis of fluoroquinolones against Bacillus anthracis.
    Kihira T; Sato J; Shibata T
    J Infect Chemother; 2004 Apr; 10(2):97-100. PubMed ID: 15160302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and pharmacodynamics of antimicrobial drugs in intensive care unit patients.
    Macedo RS; Onita JH; Wille MP; Furtado GH
    Shock; 2013 May; 39 Suppl 1():24-8. PubMed ID: 23481498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.